Nef, the shuttling molecular adaptor of HIV, influences the cytokine network

Cytokine and Growth Factor Reviews

Volumn 26, Issue 2, 2015, Pages 159-173

  Percario, Zulema Antonia ^a   Ali, Muhammad ^a   Mangino, Giorgio ^b   Affabris, Elisabetta ^a  

^a ROMA TRE UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cell to cell transfer; HIV; Nef; TNFalpha; Type I IFN

Indexed keywords

BETA INTERFERON; CD4 ANTIGEN; CD40 ANTIGEN; CELL SURFACE RECEPTOR; COMPLEMENT COMPONENT C3; CYTOKINE; HEMATOPOIETIC CELL KINASE; HLA A ANTIGEN; HLA B ANTIGEN; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF PROTEIN; P21 ACTIVATED KINASE 2; PROTEIN KINASE LCK; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; VAV PROTEIN; VIF PROTEIN; VPU PROTEIN; INTERFERON;

APOPTOSIS; BYSTANDER EFFECT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TRANSFER; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; ENDOCYTOSIS; EXTRACELLULAR SPACE; GENE EXPRESSION REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOMODULATION; INTERNALIZATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TISSUE CULTURE; UPREGULATION; VIRUS REPLICATION; VIRUS VIRULENCE; BIOSYNTHESIS; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS;

ANTIGENS, CD4; CYTOKINES; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE I; MACROPHAGES; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; VIRUS REPLICATION;

EID: 84926518716     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.11.010     Document Type: Review

References (179)

1. Malim M.H., Emerman M. HIV-1 accessory proteins- ensuring viral survival in a hostile environment. Cell Host Microbe 2008, 3:388-398.
2. Manches O., Frleta D., Bhardwaj N. Dendritic cells in progression and pathology of HIV infection. Trends Immunol 2014, 35:114-122.
3. Daniel M.D., Kirchhoff F., Czajak S.C., Sehgal P.K., Desrosiers R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258:1938-1941.
4. Deacon N.J., Tsykin A., Solomon A., Smith K., Ludford-Menting M., Hooker D.J., et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995, 270:988-991.
5. Gulizia R.J., Collman R.G., Levy J.A., Trono D., Mosier D.E. Deletion of nef slows but does not prevent CD4-positive T-cell depletion in human immunodeficiency virus type 1-infected human-PBL-SCID mice. J Virol 1997, 71:4161-4164.
6. Kestler HWr, Ringler D.J., Mori K., Panicali D.L., Sehgal P.K., Daniel M.D., et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991, 65:651-662.
7. Kirchhoff F., Greenough T.C., Brettler D.B., Sullivan J.L., Desrosiers R.C. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995, 332:228-232.
8. Hanna Z., Kay D.G., Rebai N., Guimond A., Jothy S., Jolicoeur P. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 1998, 95:163-175.
9. Jolicoeur P. The CD4C/HIVNef transgenic model of aids. Curr HIV Res 2011, 9:524-530.
10. Wu Y., Marsh J.W. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science 2001, 293:1503-1506.
11. Wu Y., Marsh J.W. Early transcription from nonintegrated DNA in human immunodeficiency virus infection. J Virol 2003, 77:10376-10382.
12. Kelly J., Beddall M.H., Yu D., Iyer S.R., Marsh J.W., Wu Y. Human macrophages support persistent transcription from unintegrated HIV-1 DNA. Virology 2008, 372:300-312.
13. Kaminchik J., Margalit R., Yaish S., Drummer H., Amit B., Sarver N., et al. Cellular distribution of HIV type 1 Nef protein: identification of domains in Nef required for association with membrane and detergent-insoluble cellular matrix. AIDS Res Hum Retroviruses 1994, 10:1003-1010.
14. Bentham M., Mazaleyrat S., Harris M. Role of myristoylation and N-terminal basic residues in membrane association of the human immunodeficiency virus type 1 Nef protein. J Gen Virol 2006, 87:563-571.
15. Gerlach H., Laumann V., Martens S., Becker C., Goody R., Geyer M. HIV-1 Nef membrane association depends on charge, curvature, composition and sequence. Nat Chem Biol 2010, 6:46-53.
16. Szilluweit R., Boll A., Lukowski S., Gerlach H., Fackler O., Geyer M., et al. HIV-1 Nef perturbs artificial membranes: investigation of the contribution of the myristoyl anchor. Biophys J 2009, 96:3242-3250.
17. Geyer M., Fackler O.T., Peterlin B.M. Structure-function relationships in HIV-1 Nef. EMBO Rep 2001, 2:580-585.
18. Freund J., Kellner R., Konvalinka J., Wolber V., Krausslich H.G., Kalbitzer H.R. A possible regulation of negative factor (Nef) activity of human immunodeficiency virus type 1 by the viral protease. Eur J Biochem 1994, 223:589-593.
19. Breuer S., Gerlach H., Kolaric B., Urbanke C., Opitz N., Geyer M. Biochemical indication for myristoylation-dependent conformational changes in HIV-1 Nef. Biochemistry 2006, 45:2339-2349.
20. Dennis C.A., Baron A., Grossmann J.G., Mazaleyrat S., Harris M., Jaeger J. Co-translational myristoylation alters the quaternary structure of HIV-1 Nef in solution. Proteins 2005, 60:658-669.
21. Arold S., Franken P., Strub M.P., Hoh F., Benichou S., Benarous R., et al. The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling. Structure 1997, 5:1361-1372.
22. Grzesiek S., Bax A., Hu J.S., Kaufman J., Palmer I., Stahl S.J., et al. Refined solution structure and backbone dynamics of HIV-1 Nef. Protein Sci 1997, 6:1248-1263.
23. Lee C.H., Saksela K., Mirza U.A., Chait B.T., Kuriyan J. Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Cell 1996, 85:931-942.
24. Geyer M., Munte C.E., Schorr J., Kellner R., Kalbitzer H.R. Structure of the anchor-domain of myristoylated and non-myristoylated HIV-1 Nef protein. J Mol Biol 1999, 289:123-138.
25. Arold S.T., Baur A.S. Dynamic Nef and Nef dynamics: how structure could explain the complex activities of this small HIV protein. Trends Biochem Sci 2001, 26:356-363.
26. Geist M.M., Pan X., Bender S., Bartenschlager R., Nickel W., Fackler O.T. Heterologous Src homology 4 domains support membrane anchoring and biological activity of HIV-1 Nef. J Biol Chem 2014, 289:14030-14044.
27. Witte V., Laffert B., Rosorius O., Lischka P., Blume K., Galler G., et al. HIV-1 Nef mimics an integrin receptor signal that recruits the polycomb group protein Eed to the plasma membrane. Mol Cell 2004, 13:179-190.
28. Simmons A., Aluvihare V., McMichael A. Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity 2001, 14:763-777.
29. Das S.R., Jameel S. Biology of the HIV Nef protein. Indian J Med Res 2005, 121:315-332.
30. Horenkamp F.A., Breuer S., Schulte A., Lülf S., Weyand M., Saksela K., et al. Conformation of the dileucine-based sorting motif in HIV-1 Nef revealed by intermolecular domain assembly. Traffic 2011, 12(7):867-877.
31. Ren X., Park S.Y., Bonifacino J.S., Hurley J.H. How HIV-1 Nef hijacks the AP-2 clathrin adaptor to downregulate CD4. eLife 2014, 3:e01754.
32. Blagoveshchenskaya A.D., Thomas L., Feliciangeli S.F., Hung C.H., Thomas G. HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway. Cell 2002, 111:853-866.
33. Doms R.W., Trono D. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev 2000, 14:2677-2688.
34. Landi A., Iannucci V., Nuffel A.V., Meuwissen P., Verhasselt B. One protein to rule them all: modulation of cell surface receptors and molecules by HIV Nef. Curr HIV Res 2011, 9:496-504.
35. Haller C., Müller B., Fritz J.V., Lamas-Murua M., Stolp B., Pujol F., et al. HIV-1 Nef and Vpu are functionally redundant broad-spectrum modulators of cell surface receptors including tetraspanins. J Virol 2014, 88:14241-14257.
36. Anderson S., Shugars D.C., Swanstrom R., Garcia J.V. Nef from primary isolates of human immunodeficiency virus type 1 suppresses surface CD4 expression in human and mouse T cells. J Virol 1993, 67:4923-4931.
37. Chaudhry A., Das S.R., Hussain A., Mayor S., George A., Bal V., et al. The Nef protein of HIV-1 induces loss of cell surface costimulatory molecules CD80 and CD86 in APCs. J Immunol 2005, 175:4566-4574.
38. Lama J., Ware C.F. Human immunodeficiency virus type 1 Nef mediates sustained membrane expression of tumor necrosis factor and the related cytokine LIGHT on activated T cells. J Virol 2000, 74:9396-9402.
39. Madrid R., Janvier K., Hitchin D., Day J., Coleman S., Noviello C., et al. Nef-induced alteration of the early/recycling endosomal compartment correlates with enhancement of HIV-1 infectivity. J Biol Chem 2005, 280:5032-5044.
40. Schindler M., Würfl S., Benaroch P., Greenough T.C., Daniels R., Easterbrook P., et al. Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles. J Virol 2003, 77:10548-10556.
41. Schwartz O., Marechal V., Le Gall S., Lemonnier F., Heard J.M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996, 2:338-342.
42. Sol-Foulon N., Moris A., Nobile C., Boccaccio C., Engering A., Abastado J.P., et al. HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread. Immunity 2002, 16:145-155.
43. Stove V., Van de Walle I., Naessens E., Coene E., Stove C., Plum J., et al. Human immunodeficiency virus Nef induces rapid internalization of the T-cell coreceptor CD8alphabeta. J Virol 2005, 79:11422-11433.
44. Stumptner-Cuvelette P., Morchoisne S., Dugast M., Le Gall S., Raposo G., Schwartz O., et al. HIV-1 Nef impairs MHC class II antigen presentation and surface expression. Proc Natl Acad Sci USA 2001, 98:12144-12149.
45. Burtey A., Rappoport J.Z., Bouchet J., Basmaciogullari S., Guatelli J., Simon S.M., et al. Dynamic interaction of HIV-1 Nef with the clathrin-mediated endocytic pathway at the plasma membrane. Traffic 2007, 8:61-76.
46. Roeth J.F., Collins K.L. Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways. Microbiol Mol Biol Rev 2006, 70:548-563.
47. Renkema G.H., Saksela K. Interactions of HIV-1 NEF with cellular signal transducing proteins. Front Biosci 2000, 5:D268-D283.
48. Abraham L., Fackler O.T. HIV-1 Nef: a multifaceted modulator of T cell receptor signaling. Cell Commun Signal 2012, 10:39.
49. Chu P.C., Wu J., Liao X.C., Pardo J., Zhao H., Li C., et al. A novel role for p21-activated protein kinase 2 in T cell activation. J Immunol 2004, 172:7324-7334.
50. Arora V.K., Molina R.P., Foster J.L., Blakemore J.L., Chernoff J., Fredericksen B.L., et al. Lentivirus Nef specifically activates Pak2. J Virol 2000, 74:11081-11087.
51. Renkema G.H., Manninen A., Saksela K. Human immunodeficiency virus type 1 Nef selectively associates with a catalytically active subpopulation of p21-activated kinase 2 (PAK2) independently of PAK2 binding to Nck or beta-PIX. J Virol 2001, 75:2154-2160.
52. Krautkrämer E., Giese S.I., Gasteier J.E., Muranyi W., Fackler O.T. Human immunodeficiency virus type 1 Nef activates p21-activated kinase via recruitment into lipid rafts. J Virol 2004, 78:4085-4097.
53. Pulkkinen K., Renkema G.H., Kirchhoff F., Saksela K. Nef associates with p21-activated kinase 2 in a p21-GTPase-dependent dynamic activation complex within lipid rafts. J Virol 2004, 78:12773-12780.
54. Olivieri K.C., Mukerji J., Gabuzda D. Nef-mediated enhancement of cellular activation and human immunodeficiency virus type 1 replication in primary T cells is dependent on association with p21-activated kinase 2. Retrovirology 2011, 8:64.
55. Brown A., Wang X., Sawai E., Cheng-Mayer C. Activation of the PAK-related kinase by human immunodeficiency virus type 1 Nef in primary human peripheral blood lymphocytes and macrophages leads to phosphorylation of a PIX-p95 complex. J Virol 1999, 73:9899-9907.
56. Blanchard N., Lankar D., Faure F., Regnault A., Dumont C., Raposo G., et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J Immunol 2002, 168:3235-3241.
57. Saksela K. Interactions of the HIV/SIV pathogenicity factor Nef with SH3 domain-containing host cell proteins. Curr HIV Res 2011, 9:531-542.
58. Xu X.N., Laffert B., Screaton G.R., Kraft M., Wolf D., Kolanus W., et al. Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain. J Exp Med 1999, 189:1489-1496.
59. Xu X.N., Screaton G.R., Gotch F.M., Dong T., Tan R., Almond N., et al. Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells. J Exp Med 1997, 186:7-16.
60. Geleziunas R., Miller M.D., Greene W.C. Unraveling the function of HIV type 1 Nef. AIDS Res Hum Retroviruses 1996, 12:1579-1582.
61. Geleziunas R., Xu W., Takeda K., Ichijo H., Greene W.C. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature 2001, 410:834-838.
62. Wolf D., Witte V., Laffert B., Blume K., Stromer E., Trapp S., et al. HIV-1 Nef associated PAK and PI3-kinases stimulate Akt-independent Bad-phosphorylation to induce anti-apoptotic signals. Nat Med 2001, 7:1217-1224.
63. Greenway A.L., McPhee D.A., Allen K., Johnstone R., Holloway G., Mills J., et al. Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis. J Virol 2002, 76:2692-2702.
64. Schindler M., Münch J., Kutsch O., Li H., Santiago M.L., Bibollet-Ruche F., et al. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006, 125:1055-1067.
65. Van Nuffel A., Ariën K.K., Stove V., Schindler M., O'Neill E., Schmökel J., et al. Primate lentiviral Nef proteins deregulate T-cell development by multiple mechanisms. Retrovirology 2013, 10:137.
66. + T cells in transgenic mice expressing HIV-1 Nef in its natural target cells. Virology 2013, 438:84-97.
67. Chrobak P., Afkhami S., Priceputu E., Poudrier J., Meunier C., Hanna Z., et al. HIV Nef expression favors the relative preservation of CD4+ T regulatory cells that retain some important suppressive functions. J Immunol 2014, 192:1681-1692.
68. Percario Z., Mangino G., Gallo G., Chiantore M., Fiorucci G., Romeo G., et al. HIV-1 Nef transfer and intracellular signalling in uninfected cells. HIV-host interactions 2011, 61-78. InTech Open Access Publisher, Rijeka, Croatia. T.L. Chang (Ed.).
69. Mangino G., Percario Z., Fiorucci G., Vaccari G., Manrique S., Romeo G., et al. In vitro treatment of human monocytes/macrophages with myristoylated recombinant Nef of human immunodeficiency virus type 1 leads to the activation of mitogen-activated protein kinases, IkappaB kinases, and interferon regulatory factor 3 and to the release of beta interferon. J Virol 2007, 81:2777-2791.
70. Olivetta E., Percario Z., Fiorucci G., Mattia G., Schiavoni I., Dennis C., et al. HIV-1 Nef induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-kappaB activation. J Immunol 2003, 170:1716-1727.
71. Speth C., Schabetsberger T., Mohsenipour I., Stöckl G., Würzner R., Stoiber H., et al. Mechanism of human immunodeficiency virus-induced complement expression in astrocytes and neurons. J Virol 2002, 76:3179-3188.
72. Fujii Y., Otake K., Tashiro M., Adachi A. Human immunodeficiency virus type 1 Nef protein on the cell surface is cytocidal for human CD4+ T cells. FEBS Lett 1996, 393:105-108.
73. Fujii Y., Otake K., Tashiro M., Adachi A. In vitro cytocidal effects of human immunodeficiency virus type 1 Nef on unprimed human CD4+ T cells without MHC restriction. J Gen Virol 1996, 77(Pt 12):2943-2951.
74. Fujii Y., Otake K., Tashiro M., Adachi A. Soluble Nef antigen of HIV-1 is cytotoxic for human CD4+ T cells. FEBS Lett 1996, 393:93-96.
75. Huang M.B., Jin L.L., James C.O., Khan M., Powell M.D., Bond V.C. Characterization of Nef-CXCR4 interactions important for apoptosis induction. J Virol 2004, 78:11084-11096.
76. James C.O., Huang M.B., Khan M., Garcia-Barrio M., Powell M.D., Bond V.C. Extracellular Nef protein targets CD4+ T cells for apoptosis by interacting with CXCR4 surface receptors. J Virol 2004, 78:3099-3109.
77. Alessandrini L., Santarcangelo A.C., Olivetta E., Ferrantelli F., d'Aloja P., Pugliese K., et al. T-tropic human immunodeficiency virus (HIV) type 1 Nef protein enters human monocyte-macrophages and induces resistance to HIV replication: a possible mechanism of HIV T-tropic emergence in AIDS. J Gen Virol 2000, 81:2905-2917.
78. Qiao X., He B., Chiu A., Knowles D.M., Chadburn A., Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 2006, 7:302-310.
79. Quaranta M.G., Tritarelli E., Giordani L., Viora M. HIV-1 Nef induces dendritic cell differentiation: a possible mechanism of uninfected CD4(+) T cell activation. Exp Cell Res 2002, 275:243-254.
80. Quaranta M.G., Mattioli B., Spadaro F., Straface E., Giordani L., Ramoni C., et al. HIV-1 Nef triggers Vav-mediated signaling pathway leading to functional and morphological differentiation of dendritic cells. FASEB J 2003, 17:2025-2036.
81. Federico M., Percario Z., Olivetta E., Fiorucci G., Muratori C., Micheli A., et al. HIV-1 Nef activates STAT1 in human monocytes/macrophages through the release of soluble factors. Blood 2001, 98:2752-2761.
82. Percario Z., Olivetta E., Fiorucci G., Mangino G., Peretti S., Romeo G., et al. Human immunodeficiency virus type 1 (HIV-1) Nef activates STAT3 in primary human monocyte/macrophages through the release of soluble factors: involvement of Nef domains interacting with the cell endocytotic machinery. J Leukoc Biol 2003, 74:821-832.
83. Mangino G., Percario Z.A., Fiorucci G., Vaccari G., Acconcia F., Chiarabelli C., et al. HIV-1 Nef induces proinflammatory state in macrophages through its acidic cluster domain: involvement of TNF alpha receptor associated factor 2. PLoS One 2011, 6:e22982.
84. Greenberg M.E., Bronson S., Lock M., Neumann M., Pavlakis G.N., Skowronski J. Co-localization of HIV-1 Nef with the AP-2 adaptor protein complex correlates with Nef-induced CD4 down-regulation. EMBO J 1997, 16:6964-6976.
85. Varin A., Manna S.K., Quivy V., Decrion A.Z., Van Lint C., Herbein G., et al. Exogenous Nef protein activates NF-kappa B, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role in AIDS pathogenesis. J Biol Chem 2003, 278:2219-2227.
86. Peterlin B. Nef: out and in?. Nat Immunol 2006, 7:229-230.
87. Ameisen J., Guy B., Chamaret S., Loche M., Mouton Y., Neyrinck J., et al. Antibodies to the nef protein and to nef peptides in HIV-1-infected seronegative individuals. AIDS Res Hum Retroviruses 1989, 5:279-291.
88. Sowinski S., Jolly C., Berninghausen O., Purbhoo M.A., Chauveau A., Köhler K., et al. Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nat Cell Biol 2008, 10:211-219.
89. Campbell T.D., Khan M., Huang M.B., Bond V.C., Powell M.D. HIV-1 Nef protein is secreted into vesicles that can fuse with target cells and virions. Ethn Dis 2008, 18. S2-S14-9.
90. Ali S.A., Huang M.B., Campbell P.E., Roth W.W., Campbell T., Khan M., et al. Genetic characterization of HIV type 1 Nef-induced vesicle secretion. AIDS Res Hum Retroviruses 2010, 26:173-192.
91. Xu W., Santini P.A., Sullivan J.S., He B., Shan M., Ball S.C., et al. HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol 2009, 10:1008-1017.
92. Muratori C., Cavallin L.E., Krätzel K., Tinari A., De Milito A., Fais S., et al. Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells. Cell Host Microbe 2009, 6:218-230.
93. Baur A.S. HIV-Nef and AIDS pathogenesis: are we barking up the wrong tree?. Trends Microbiol 2011, 19(9):435-440.
94. Fomina A.F., Deerinck T.J., Ellisman M.H., Cahalan M.D. Regulation of membrane trafficking and subcellular organization of endocytic compartments revealed with FM1-43 in resting and activated human T cells. Exp Cell Res 2003, 291:150-166.
95. Poteryaev D., Datta S., Ackema K., Zerial M., Spang A. Identification of the switch in early-to-late endosome transition. Cell 2010, 141:497-508.
96. Jolly C., Sattentau Q.J. Regulated secretion from CD4+ T cells. Trends Immunol 2007, 28:474-481.
97. Lenassi M., Cagney G., Liao M., Vaupotic T., Bartholomeeusen K., Cheng Y., et al. HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic 2010, 11:110-122.
98. Raymond A.D., Campbell-Sims T.C., Khan M., Lang M., Huang M.B., Bond V.C., et al. HIV type 1 Nef is released from infected cells in CD45(+) microvesicles and is present in the plasma of HIV-infected individuals. AIDS Res Hum Retroviruses 2011, 27:167-178.
99. Mercier S.K., Donaghy H., Botting R.A., Turville S.G., Harman A.N., Nasr N., et al. The microvesicle component of HIV-1 inocula modulates dendritic cell infection and maturation and enhances adhesion to and activation of T lymphocytes. PLoS Pathog 2013, 9:e1003700.
100. Mukerji J., Olivieri K.C., Misra V., Agopian K.A., Gabuzda D. Proteomic analysis of HIV-1 Nef cellular binding partners reveals a role for exocyst complex proteins in mediating enhancement of intercellular nanotube formation. Retrovirology 2012, 9:33.
101. Wang T., Green L.A., Gupta S.K., Kim C., Wang L., Almodovar S., et al. Transfer of intracellular HIV Nef to endothelium causes endothelial dysfunction. PLoS One 2014, 9:e91063.
102. Wang T., Green L.A., Gupta S.K., Amet T., Byrd D.J., Yu Q., et al. Intracellular Nef detected in peripheral blood mononuclear cells from HIV patients. AIDS Res Hum Retroviruses 2014, [ahead of print].
103. Stacey A.R., Norris P.J., Qin L., Haygreen E.A., Taylor E., Heitman J., et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009, 83:3719-3733.
104. Boasso A., Shearer G.M. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol 2008, 126:235-242.
105. Swingler S., Mann A., Jacque J., Brichacek B., Sasseville V.G., Williams K., et al. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med 1999, 5:997-1003.
106. Swingler S., Brichacek B., Jacque J.M., Ulich C., Zhou J., Stevenson M. HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature 2003, 424:213-219.
107. Wan L., Molloy S.S., Thomas L., Liu G., Xiang Y., Rybak S.L., et al. PACS-1 defines a novel gene family of cytosolic sorting proteins required for trans-Golgi network localization. Cell 1998, 94:205-216.
108. Dikeakos J.D., Thomas L., Kwon G., Elferich J., Shinde U., Thomas G. An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I. Mol Biol Cell 2012, 23:2184-2197.
109. Baugh L.L., Garcia J.V., Foster J.L. Functional characterization of the human immunodeficiency virus type 1 Nef acidic domain. J Virol 2008, 82:9657-9667.
110. Lubben N.B., Sahlender D.A., Motley A.M., Lehner P.J., Benaroch P., Robinson M.S. HIV-1 Nef-induced down-regulation of MHC class I requires AP-1 and clathrin but not PACS-1 and is impeded by AP-2. Mol Biol Cell 2007, 18:3351-3365.
111. Johannes L., Pezo V., Mallard F., Tenza D., Wiltz A., Saint-Pol A., et al. Effects of HIV-1 Nef on retrograde transport from the plasma membrane to the endoplasmic reticulum. Traffic 2003, 4:323-332.
112. Khan K.A., Abbas W., Varin A., Kumar A., Di Martino V., Dichamp I., et al. HIV-1 Nef interacts with HCV core, recruits TRAF2, TRAF5 and TRAF6, and stimulates HIV-1 replication in macrophages. J Innate Immun 2013, 5:639-656.
113. Sandberg M., Hammerschmidt W., Sugden B. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J Virol 1997, 71:4649-4656.
114. Brinkmann M., Glenn M., Rainbow L., Kieser A., Henke-Gendo C., Schulz T. Activation of mitogen-activated protein kinase and NF-kappaB pathways by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein. J Virol 2003, 77:9346-9358.
115. Garcia M., Kaserman J., Chung Y., Jung J., Lee S. Herpesvirus saimiri STP-A oncoprotein utilizes Src family protein tyrosine kinase and tumor necrosis factor receptor-associated factors to elicit cellular signal transduction. J Virol 2007, 81:2663-2674.
116. Park K., Choi S., Choi D., Park J., Yie S., Lee S., et al. Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumor necrosis factor receptor-associated factor 2. J Biol Chem 2003, 278:30711-30718.
117. Lee J.H., Wittki S., Bräu T., Dreyer F.S., Krätzel K., Dindorf J., et al. HIV Nef, paxillin, and Pak1/2 regulate activation and secretion of TACE/ADAM10 proteases. Mol Cell 2013, 49:668-679.
118. Sawai E.T., Baur A., Struble H., Peterlin B.M., Levy J.A., Cheng-Mayer C. Human immunodeficiency virus type 1 Nef associates with a cellular serine kinase in T lymphocytes. Proc Natl Acad Sci USA 1994, 91:1539-1543.
119. Linnemann T., Zheng Y.H., Mandic R., Peterlin B.M. Interaction between Nef and phosphatidylinositol-3-kinase leads to activation of p21-activated kinase and increased production of HIV. Virology 2002, 294:246-255.
120. Rauch S., Pulkkinen K., Saksela K., Fackler O.T. Human immunodeficiency virus type 1 Nef recruits the guanine exchange factor Vav1 via an unexpected interface into plasma membrane microdomains for association with p21-activated kinase 2 activity. J Virol 2008, 82:2918-2929.
121. Aggarwal B.B., Gupta S.C., Kim J.H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012, 119:651-665.
122. DeBerge M.P., Ely K.H., Enelow R.I. Soluble, but not transmembrane, TNF-α is required during influenza infection to limit the magnitude of immune responses and the extent of immunopathology. J Immunol 2014, 192:5839-5851.
123. Hu X., Li B., Li X., Zhao X., Wan L., Lin G., et al. Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2. J Immunol 2014, 192:1320-1331.
124. Kumar A., Abbas W., Herbein G. TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy?. Mediators Inflamm 2013, 2013:484378.
125. Arenaccio C., Chiozzini C., Columba-Cabezas S., Manfredi F., Affabris E., Baur A., et al. Exosomes from human immunodeficiency virus type 1 (HIV-1)-infected cells license quiescent CD4+ T lymphocytes to replicate HIV-1 through a Nef- and ADAM17-dependent mechanism. J Virol 2014, 88:11529-11539.
126. Piguet V., Wan L., Borel C., Mangasarian A., Demaurex N., Thomas G., et al. HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nat Cell Biol 2000, 2:163-167.
127. Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol 2010, 45:146-169.
128. Sanchez G., Xu X., Chermann J.C., Hirsch I. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol 1997, 71:2233-2240.
129. Janini M., Rogers M., Birx D.R., McCutchan F.E. Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J Virol 2001, 75:7973-7986.
130. Fourati S., Lambert-Niclot S., Soulie C., Wirden M., Malet I., Valantin M.A., et al. Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments. AIDS 2014, 28:487-491.
131. Arenaccio C., Chiozzini C., Columba-Cabezas S., Manfredi F., Federico M. Cell activation and HIV-1 replication in unstimulated CD4+ T lymphocytes ingesting exosomes from cells expressing defective HIV-1. Retrovirology 2014, 11:46.
132. Federico M., Titti F., Buttó S., Orecchia A., Carlini F., Taddeo B., et al. Biologic and molecular characterization of producer and nonproducer clones from HUT-78 cells infected with a patient HIV isolate. AIDS Res Hum Retroviruses 1989, 5:385-396.
133. D'Aloja P., Olivetta E., Bona R., Nappi F., Pedacchia D., Pugliese K., et al. gag, vif, and nef genes contribute to the homologous viral interference induced by a nonproducer human immunodeficiency virus type 1 (HIV-1) variant: identification of novel HIV-1-inhibiting viral protein mutants. J Virol 1998, 72:4308-4319.
134. D'Aloja P., Santarcangelo A.C., Arold S., Baur A., Federico M. Genetic and functional analysis of the human immunodeficiency virus (HIV) type 1-inhibiting F12-HIVnef allele. J Gen Virol 2001, 82:2735-2745.
135. Herbein G., Khan K.A. Is HIV infection a TNF receptor signalling-driven disease. Trends Immunol 2008, 29:61-67.
136. Peng B., Voltan R., Cristillo A.D., Alvord W.G., Davis-Warren A., Zhou Q., et al. Replicating Ad-recombinants encoding non-myristoylated rather than wild-type HIV Nef elicit enhanced cellular immunity. AIDS 2006, 20:2149-2157.
137. Pitha-Rowe I.F., Pitha P.M. Viral defense, carcinogenesis and ISG15: novel roles for an old ISG. Cytokine Growth Factor Rev 2007, 18:409-417.
138. Doehle B.P., Hladik F., McNevin J.P., McElrath M.J., Gale M. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J Virol 2009, 83:10395-10405.
139. Doehle B.P., Chang K., Rustagi A., McNevin J., McElrath M.J., Gale M. Vpu mediates depletion of interferon regulatory factor 3 during HIV infection by a lysosome-dependent mechanism. J Virol 2012, 86:8367-8374.
140. Hotter D., Kirchhoff F., Sauter D. HIV-1 Vpu does not degrade interferon regulatory factor 3. J Virol 2013, 87:7160-7165.
141. Doehle B.P., Chang K., Fleming L., McNevin J., Hladik F., McElrath M.J., et al. Vpu-deficient HIV strains stimulate innate immune signaling responses in target cells. J Virol 2012, 86:8499-8506.
142. Sgarbanti M., Remoli A.L., Marsili G., Ridolfi B., Borsetti A., Perrotti E., et al. IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer. J Virol 2008, 82:3632-3641.
143. Battistini A., Marsili G., Sgarbanti M., Ensoli B., Hiscott J. IRF regulation of HIV-1 long terminal repeat activity. J Interferon Cytokine Res 2002, 22:27-37.
144. Pertel T., Hausmann S., Morger D., Züger S., Guerra J., Lascano J., et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 2011, 472:361-365.
145. Galão R.P., Le Tortorec A., Pickering S., Kueck T., Neil S.J. Innate sensing of HIV-1 assembly by Tetherin induces NFκB-dependent proinflammatory responses. Cell Host Microbe 2012, 12:633-644.
146. Hotter D., Sauter D., Kirchhoff F. Emerging role of the host restriction factor tetherin in viral immune sensing. J Mol Biol 2013, 425:4956-4964.
147. Ankel H., Capobianchi M.R., Castilletti C., Dianzani F. Interferon induction by HIV glycoprotein 120: role of the V3 loop. Virology 1994, 205:34-43.
148. Capobianchi M.R., Ankel H., Ameglio F., Paganelli R., Pizzoli P.M., Dianzani F. Recombinant glycoprotein 120 of human immunodeficiency virus is a potent interferon inducer. AIDS Res Hum Retroviruses 1992, 8:575-579.
149. Capobianchi M.R., Ameglio F., Cordiali Fei P., Castilletti C., Mercuri F., Fais S., et al. Coordinate induction of interferon alpha and gamma by recombinant HIV-1 glycoprotein 120. AIDS Res Hum Retroviruses 1993, 9:957-962.
150. Gessani S., Puddu P., Varano B., Borghi P., Conti L., Fantuzzi L., et al. Induction of beta interferon by human immunodeficiency virus type 1 and its gp120 protein in human monocytes-macrophages: role of beta interferon in restriction of virus replication. J Virol 1994, 68:1983-1986.
151. Szebeni J., Dieffenbach C., Wahl S.M., Venkateshan C.N., Yeh A., Popovic M., et al. Induction of alpha interferon by human immunodeficiency virus type 1 in human monocyte-macrophage cultures. J Virol 1991, 65:6362-6364.
152. von Sydow M., Sönnerborg A., Gaines H., Strannegård O. Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses 1991, 7:375-380.
153. Herbeuval J.P., Nilsson J., Boasso A., Hardy A.W., Kruhlak M.J., Anderson S.A., et al. Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc Natl Acad Sci USA 2006, 103:7000-7005.
154. Bosinger S.E., Li Q., Gordon S.N., Klatt N.R., Duan L., Xu L., et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 2009, 119:3556-3572.
155. Jacquelin B., Mayau V., Targat B., Liovat A.S., Kunkel D., Petitjean G., et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 2009, 119:3544-3555.
156. Benlahrech A., Patterson S. HIV-1 infection and induction of interferon alpha in plasmacytoid dendritic cells. Curr Opin HIV AIDS 2011, 6:373-378.
157. Beignon A.S., McKenna K., Skoberne M., Manches O., DaSilva I., Kavanagh D.G., et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005, 115:3265-3275.
158. O'Brien M., Manches O., Sabado R.L., Baranda S.J., Wang Y., Marie I., et al. Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype. J Clin Invest 2011, 121:1088-1101.
159. Sandgren K.J., Smed-Sörensen A., Forsell M.N., Soldemo M., Adams W.C., Liang F., et al. Human plasmacytoid dendritic cells efficiently capture HIV-1 envelope glycoproteins via CD4 for antigen presentation. J Immunol 2013, 191:60-69.
160. Sasai M., Linehan M.M., Iwasaki A. Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3. Science 2010, 329:1530-1534.
161. Chang J.J., Altfeld M. Innate immune activation in primary HIV-1 infection. J Infect Dis 2010, 202(Suppl 2):S297-S301.
162. Démoulins T., Abdallah A., Kettaf N., Baron M.L., Gerarduzzi C., Gauchat D., et al. Reversible blockade of thymic output: an inherent part of TLR ligand-mediated immune response. J Immunol 2008, 181:6757-6769.
163. Tough D.F., Borrow P., Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996, 272:1947-1950.
164. Reed J.R., Vukmanovic-Stejic M., Fletcher J.M., Soares M.V., Cook J.E., Orteu C.H., et al. Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J Exp Med 2004, 199:1433-1443.
165. Sedaghat A.R., German J., Teslovich T.M., Cofrancesco J., Jie C.C., Talbot C.C., et al. Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol 2008, 82:1870-1883.
166. Wilson E.B., Yamada D.H., Elsaesser H., Herskovitz J., Deng J., Cheng G., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013, 340:202-207.
167. Teijaro J.R., Ng C., Lee A.M., Sullivan B.M., Sheehan K.C., Welch M., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013, 340:207-211.
168. Herbeuval J.P., Shearer G.M. HIV-1 immunopathogenesis: how good interferon turns bad. Clin Immunol 2007, 123:121-128.
169. Denton P.W., García J.V. Humanized mouse models of HIV infection. AIDS Rev 2011, 13:135-148.
170. Fackler O.T., Murooka T.T., Imle A., Mempel T.R. Adding new dimensions: towards an integrative understanding of HIV-1 spread. Nat Rev Microbiol 2014, 12:563-574.
171. Skog J., Würdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10:1470-1476.
172. Fang Y., Wu N., Gan X., Yan W., Morrell J.C., Gould S.J. Higher-order oligomerization targets plasma membrane proteins and HIV gag to exosomes. PLoS Biol 2007, 5:e158.
173. Caccuri F., Rueckert C., Giagulli C., Schulze K., Basta D., Zicari S., et al. HIV-1 matrix protein p17 promotes lymphangiogenesis and activates the endothelin-1/endothelin B receptor axis. Arterioscler Thromb Vasc Biol 2014, 34:846-856.
174. Caccuri F., Giagulli C., Reichelt J., Martorelli D., Marsico S., Bugatti A., et al. Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate B cell growth. J Virol 2014, 88:5706-5717.
175. Giagulli C., Caccuri F., Cignarella F., Lougaris V., Martorelli D., Bugatti A., et al. A CXCR1 haplotype hampers HIV-1 matrix protein p17 biological activity. AIDS 2014, 28:2355-2364.
176. Giombini E., Dolcetti R., Caccuri F., Selleri M., Rozera G., Abbate I., et al. Detection of HIV-1 matrix protein p17 quasispecies variants in plasma of chronic HIV-1-infected patients by ultra-deep pyrosequencing. J Acquir Immune Defic Syndr 2014, 66:332-339.
177. Witkowski W., Verhasselt B. Contributions of HIV-1 Nef to immune dysregulation in HIV-infected patients: a therapeutic target. Expert Opin Ther Targets 2013, 17:1345-1356.
178. Lülf S., Horenkamp F.A., Breuer S., Geyer M. Nef surfaces: where to interfere with function. Curr HIV Res 2011, 9:543-551.
179. Lülf S., Matz J., Rouyez M.C., Järviluoma A., Saksela K., Benichou S., et al. Structural basis for the inhibition of HIV-1 Nef by a high-affinity binding single-domain antibody. Retrovirology 2014, 11:24.